Overview
KYNB market data
Price History
KYNB price chart
Valuation & Profitability
- P/E (TTM)
- 0.18 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $45.38 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.03 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 2,199.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $6.32 – $12.60 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $28.7M · P/S 3.86.
Company News
UPDATE: Kyntra Bio Q2 Adj. EPS $(4.68) Misses $(3.18) Estimate, Sales $(1.474M) Miss $2.007M EstimateBenzinga · Aug 13, 2026, 10:07 PM
Kyntra Bio Q2 2026 Earnings Call: Complete TranscriptBenzinga · Aug 13, 2026, 9:59 PM
Kyntra Bio Q2 EPS $2.96, Sales $(1.474M) Miss $2.007M EstimateBenzinga · Aug 13, 2026, 8:06 PM
This Performance Food Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayBenzinga · Jul 7, 2026, 11:00 AM
Kyntra Bio Presents New Data For Roxadustat Showing Improvements In Transfusion Independence Regardless Of Ring Sideroblast Status In Anemia PatientsBenzinga · Jun 11, 2026, 8:07 PM
8-K filing — KYNTRA BIO, INC. (KYNB)SEC EDGAR · Jun 9, 2026, 9:04 PM
Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30Benzinga · Jun 9, 2026, 11:55 AM